Qonsilus Launches Landmark Decision-Making Platform for Medical Diagnostics with Roche Diagnostics Germany
Mainz, Germany (PRWEB) January 28, 2016 -- In the fall of 2015, the “Deutsche Ärzteblatt” (the professional journal of the German Medical Association) reported that, “not only would the generation and storage of massive amounts of healthcare data be of interest within the digital healthcare market, but also the development of suitable IT tools for analyzing data,” would be welcomed.
Based on knowledge models on file, Qonsilus rapidly and safely converts medical data into personalized recommendations for diagnosis and treatment. The decision-making process relayed to the patient helps laboratories, physicians and healthcare companies in finding solutions more rapidly and is based on sound data – for better, faster decisions.
As the first medical product of the series, Qonsilus Lab makes complex and specialized knowledge immediately available to laboratories: the diagnostics service provides rapid access to medical specialist knowledge relevant to practical situations and based on the available laboratory and clinical data proposes suggestions for diagnoses, treatment options and measures tailored to the individual patient. The result is an automated finding at three levels of complexity that are geared towards the laboratory physician and can be forwarded to the referring physician. As a result, Qonsilus Lab complements the decision-making skills, supplements the laboratory analyses with treatment recommendations, and offers diagnoses at the level of the specialist.
Foremost partners in the healthcare sector and data analysis - including Roche Diagnostics Germany, 3M, IMS Health, and Qlaym - are already collaborating with Qonsilus: since September 1, 2015, Roche Diagnostics Germany GmbH has been the exclusive distributor for Qonsilus Lab GynEndo, the diagnostics service for the field of gynecological endocrinology. Qonsilus Lab GynEndo contains over 7,000 dynamically compiled text blocks and 5,000 rules based on the scientific knowledge model for gynecological endocrinology designed by Prof. Dr. med. Freimut Leidenberger and Prof. Dr. med. Thomas Strowitzki. This means that solid, proven knowledge from experts and specialist bodies can be retrieved with a high standard of quality.
“We offer the physician access to more knowledge that can assist in making the right decision – that is our goal,” explained CEO Oliver Schauer. “We are extremely pleased to have gained Roche Diagnostics, the market leader in laboratory diagnostics, as a partner for marketing our medical innovation. As an approved medical tool, Qonsilus Lab can be used for ‘proof-of-concept’ for other medical indications since the existing platform facilitates a rapid, modular application to all healthcare sectors.”
In terms of the safety of the treatment recommendations, the company is certified under DIN EN ISO 13485 by TÜV SÜD for the preparation of diagnoses, treatment options and measures on an individual patient basis using the available laboratory and clinical data. The medical software Qonsilus Lab is authorized as a Class IIa medical device as of August 2015 (in accordance with the Medical Devices Directive 93/42/EEC).
The company Qonsilus GmbH was established in 2011 as medesso GmbH and renamed Qonsilus GmbH in November 2015.
About Qonsilus
Qonsilus is a medical software firm converting medical data into individualized diagnostic and therapy recommendations.
The decision-making process relayed to the patient assists laboratories, physicians and healthcare companies in making better, faster decisions. The user obtains direct access to specialist knowledge from a wide range of sectors relating to practical situations as well as the processing of all relevant information – providing more time and competence for the decision itself. The Qonsilus team includes physicians, scientists, medical editors, software specialists and IT experts, all of whom possess many years of experience. The company is certified in DIN EN ISO 13485 (standard for quality management systems in the medical products sector). The Qonsilus Lab software is approved as a Class IIa medical device.
For more information, please visit the company website at http://www.qonsilus.com
Source: http://www.aerzteblatt.de/archiv/172025/Medizinische-Forschung-Club-der-medizinischen-Avantgarde
All trademarks used in this release are protected by law.
Heidrun Kirsch, Qonsilus GmbH, http://www.qonsilus.com, +49 61314998730, [email protected]
Share this article